List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Short Bowel Syndrome - Overview
Short Bowel Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Short Bowel Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Short Bowel Syndrome - Companies Involved in Therapeutics Development
Adocia SAS
enGene Inc
Hanmi Pharmaceuticals Co Ltd
Huons Global Co Ltd
Micelle BioPharma Inc
Naia Rare Diseases Inc
OPKO Health Inc
Pfizer Inc
PhaseBio Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Worphmed Srl
Zealand Pharma AS
Short Bowel Syndrome - Drug Profiles
apraglutide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
exenatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Agonize GLP2R for Short Bowel Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Short Bowel Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glepaglutide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HL-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-15912 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melatonin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOD-1501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NB-1002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-403 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-681 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teduglutide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teduglutide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZP-7570 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Short Bowel Syndrome - Dormant Projects
Short Bowel Syndrome - Discontinued Products
Short Bowel Syndrome - Product Development Milestones
Featured News & Press Releases
Jun 26, 2019: Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome
May 17, 2019: Therachon to present data from ongoing Phase II Study of Apraglutide for Short Bowel Syndrome at Digestive Disease Week
May 17, 2019: U.S. FDA approves GATTEX (teduglutide) for children 1 year of age and older with Short Bowel Syndrome
May 07, 2019: Zealand Pharma enrolls first patient in Phase 3 extension study of glepaglutide for treatment for short bowel syndrome
May 03, 2019: Hanmi's short bowel syndrome treatment becomes orphan drug in US
Mar 25, 2019: Therachon presents data from preclinical and phase I clinical studies of Apraglutide for the treatment of Short Bowel Syndrome at ASPEN 2019 Nutrition Science & Practice Conference
Feb 05, 2019: Pharm-Olam enrolls patients in Zealand Pharma orphan drug study
Jan 16, 2019: Therachon is granted Orphan Drug Designation by US FDA for Apraglutide for the treatment of Short Bowel Syndrome
Nov 29, 2018: Therachon is granted Orphan Drug Designation in the European Union for apraglutide for the treatment of short bowel syndrome
Nov 13, 2018: U.S. FDA accepts for filing Shire's supplemental New Drug Application for GATTEX (teduglutide [rDNA origin]) for children with Short Bowel Syndrome
Oct 05, 2018: Zealand Pharma enrols first patient in Phase lll study of glepaglutide
May 31, 2018: Zealand Pharma to present new clinical Phase 2 results on glepaglutide for the treatment of short bowel syndrome at the DDW conference in the U.S.
Apr 26, 2018: Zealand announces successful End-of-Phase 2 meeting with FDA on glepaglutide for short bowel syndrome
Apr 09, 2018: Revestive is accepted for restricted use within NHS Scotland
Jan 23, 2018: New clinical evidence support potential for glepaglutide as a once-weekly drug for short bowel syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Short Bowel Syndrome, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Short Bowel Syndrome - Pipeline by Adocia SAS, H2 2019
Short Bowel Syndrome - Pipeline by enGene Inc, H2 2019
Short Bowel Syndrome - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2019
Short Bowel Syndrome - Pipeline by Huons Global Co Ltd, H2 2019
Short Bowel Syndrome - Pipeline by Micelle BioPharma Inc, H2 2019
Short Bowel Syndrome - Pipeline by Naia Rare Diseases Inc, H2 2019
Short Bowel Syndrome - Pipeline by OPKO Health Inc, H2 2019
Short Bowel Syndrome - Pipeline by Pfizer Inc, H2 2019
Short Bowel Syndrome - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2019
Short Bowel Syndrome - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Short Bowel Syndrome - Pipeline by Worphmed Srl, H2 2019
Short Bowel Syndrome - Pipeline by Zealand Pharma AS, H2 2019
Short Bowel Syndrome - Dormant Projects, H2 2019
Short Bowel Syndrome - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Short Bowel Syndrome, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

Companies Mentioned
• Adocia SAS
• enGene Inc
• Hanmi Pharmaceuticals Co Ltd
• Huons Global Co Ltd
• Micelle BioPharma Inc
• Naia Rare Diseases Inc
• OPKO Health Inc
• Pfizer Inc
• PhaseBio Pharmaceuticals Inc
• Takeda Pharmaceutical Co Ltd
• Worphmed Srl
• Zealand Pharma AS